Share on StockTwits

DaVita HealthCare Partners (NYSE:DVA) Insider Kim M. Rivera sold 5,929 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $71.05, for a total value of $421,255.45. Following the completion of the sale, the insider now directly owns 4,032 shares in the company, valued at approximately $286,474. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

DaVita HealthCare Partners (NYSE:DVA) traded down 0.21% during mid-day trading on Friday, hitting $70.79. The stock had a trading volume of 473,971 shares. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $72.37. The stock has a 50-day moving average of $69.25 and a 200-day moving average of $66.42. The company has a market cap of $15.163 billion and a price-to-earnings ratio of 19.40.

DaVita HealthCare Partners (NYSE:DVA) last released its earnings data on Thursday, May 1st. The company reported $0.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by $0.01. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter in the previous year, the company posted $1.84 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.69 EPS for the current fiscal year.

DVA has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $77.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $73.00 price target on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of DaVita HealthCare Partners from $73.00 to $76.00 in a research note on Friday, May 2nd. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $83.25.

DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.